IP Library › Granted Patent US 11,111,278
Granted Patent B2
US 11,111,278 · App. 16/743,831 · Granted Sep 7, 2021

Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload

Inventors: Eric N. Olson (University Park, TX); Rhonda S. Bassel-Duby (Dallas, TX); Catherine A. Makarewich (Dallas, TX); Benjamin R. Nelson (Dallas, TX)
Assignee: The Board of Regents of the University of Texas System
C07K14/47A61K38/1709A61K45/06A61K48/0058
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,111,278
App. No.
16/743,831
Granted
Sep 7, 2021
Kind
B2
Abstract

The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.

Claims (7)

1. A polynucleotide, comprising a polynucleotide sequence encoding a Dwarf open reading frame (DWORF) consisting of SEQ ID NO: 3, operatively linked to a heterologous cardiac-specific promoter.

2. The polynucleotide of claim 1 , wherein the heterologous cardiac-specific promoter is a cardiomyocyte-specific α-myosin heavy chain (αMHC) promoter.

3. The polynucleotide of claim 1 , wherein the polynucleotide is in a viral expression construct.

4. A vector, comprising a polynucleotide sequence encoding a Dwarf open reading frame (DWORF) consisting of SEQ ID NO: 3, operatively linked to a heterologous cardiac-specific promoter.

5. The vector of claim 4 , wherein the vector is a viral vector.

6. A method of promoting the activity of the SERCA calcium pump in a subject suffering from dilated cardiomyopathy, comprising administering to the subject a viral particle comprising the polynucleotide of claim 1 .

7. The method of claim 6 , wherein the heterologous cardiac-specific promoter is a cardiomyocyte-specific α-myosin heavy chain (αMHC) promoter.

Continuity (3)
Division 15491057 · Apr 19, 2017
Provisional Application 62324706 · Apr 19, 2016
Related Publication 20200140502A1 · May 7, 2020
Cited By (1)
US 12,564,647